Cynata Therapeutics Limited (ASX:CYP) Managing Director Dr Ross MacDonald presents on 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform at FNN's Investor Event.Investment highlights: - Outstandingly well-positioned in regenerative medicine.
- Scalable, globally applicable technology.
- Successful clinical trial results: world leader.
- Attractive and validated licensing business model.
- Clear pipeline of high potential target areas.
For more information, watch the presentation with Managing Director Dr Ross MacDonald.
